{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_names_stdName in Standardized Name (approximate match)
Status:
US Previously Marketed
Source:
Oil of Eucalyptus U.S.P.
(1921)
Source URL:
First marketed in 1921
Source:
Oil of Eucalyptus U.S.P.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ANDA216046
(2022)
Source URL:
First approved in 2022
Source:
ANDA216046
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
ProBionexxProbiotic Support by SKYA HEALTH, LLC
(2023)
Source URL:
First approved in 2022
Source:
Degong Ling by Shenzhen Deyintang Biotechnology Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M006
(2021)
Source URL:
First approved in 2021
Source:
M006
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01547949: Phase 4 Interventional Completed Inflammation
(2012)
Source URL:
First approved in 2019
Source:
21 CFR 341
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
505G(a)(3)
(2023)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT02065076: Phase 4 Interventional Completed Hyperkalemia
(2014)
Source URL:
First approved in 2013
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
KAEWOON by RNCARE
(2017)
Source URL:
First approved in 2012
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2016)
Source URL:
First approved in 2012
Source:
NDA019941
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 334
(2018)
Source URL:
First approved in 2011
Source:
Proactiv MD Ultra-Hydrating Moisturizer by Alchemee, LLC
Source URL:
Class:
STRUCTURALLY DIVERSE